Adaptimmune Therapeutics plc (ADAP) — Earnings Call X-Ray
Our AI read all 33 of ADAP's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
D
Q4 2024
Calls Analyzed
33
2016–2025
Avg Candor
6.6/9
evasion 3.9/9
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-13
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of ADAP's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
D
Q4 2024 earnings call
2025-03-20
Management gave no formal guidance against accelerating demand. The delivery was rich in specifics.
Demand: acceleratingBacklog: growingPricing: stableHeadcount: cuttingCapex: decreasing 10 analysts · 20 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C+
Q3 2024 earnings call
2024-11-13
Management held guidance steady against accelerating demand. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: acceleratingPricing: stableHeadcount: cuttingCapex: decreasing 10 analysts · 24 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C+
Q2 2024 earnings call
2024-08-12
move ±16.3%
Management held guidance steady. The delivery was unusually candid, rich in specifics.
Guidance: maintainedPricing: stableHeadcount: growing 10 analysts · 16 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q1 2024 earnings call
2024-05-15
move ±15.4%
Management lowered guidance. The delivery was unusually candid, relaxed under questioning.
Guidance: loweredHeadcount: growingCapex: increasing 7 analysts · 14 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Resolves doubts✓ Volume step-up aheadDirection beats results
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B
Q4 2023 earnings call
2024-03-06
move ±18.7%
Management held guidance steady. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Guidance: maintainedPricing: stableHeadcount: growingCapex: increasing 5 analysts · 8 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q3 2023 earnings call
2023-11-08
Management gave no formal guidance against contracting margins. The delivery was unusually candid.
Margins: contractingHeadcount: cutting 6 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubtsDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q2 2023 earnings call
2023-08-09
Management lowered guidance. The delivery was unusually candid.
Guidance: loweredHeadcount: flat 7 analysts · 10 questions
⚑ Critic ammunition✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q1 2023 |
2023-05-12 |
D |
none | unclear | unclear |
6/9 |
3/9 |
| Q4 2022 |
2023-03-06 |
F |
none | unclear | unclear |
5/9 |
6/9 |
| Q3 2022 |
2022-11-08 |
D |
lowered | unclear | unclear |
8/9 |
3/9 |
| Q2 2022 |
2022-08-06 |
D |
maintained | unclear | unclear |
6/9 |
4/9 |
| Q1 2022 |
2022-05-09 |
D |
maintained | unclear | unclear |
6/9 |
4/9 |
| Q4 2021 |
2022-03-14 |
C+ |
none | unclear | unclear |
7/9 |
3/9 |
| Q3 2021 |
2021-11-04 |
D |
none | unclear | unclear |
7/9 |
5/9 |
| Q2 2021 |
2021-08-09 |
F |
maintained | unclear | unclear |
5/9 |
6/9 |
| Q1 2021 |
2021-05-07 |
F |
none | unclear | unclear |
6/9 |
5/9 |
| Q4 2020 |
2021-02-25 |
D |
none | unclear | unclear |
6/9 |
4/9 |
| Q3 2020 |
2020-11-05 |
F |
none | accelerating | unclear |
7/9 |
6/9 |
| Q2 2020 |
2020-08-09 |
D |
maintained | mixed | unclear |
7/9 |
6/9 |
| Q1 2020 |
2020-05-14 |
D |
maintained | mixed | unclear |
6/9 |
4/9 |
| Q4 2019 |
2020-02-27 |
F |
none | unclear | unclear |
6/9 |
5/9 |
| Q3 2019 |
2019-11-10 |
F |
maintained | accelerating | unclear |
6/9 |
5/9 |
| Q2 2019 |
2019-08-03 |
C |
none | unclear | unclear |
8/9 |
2/9 |
| Q4 2018 |
2019-02-28 |
D |
maintained | unclear | unclear |
6/9 |
5/9 |
| Q3 2018 |
2018-11-06 |
D |
none | unclear | unclear |
6/9 |
5/9 |
| Q2 2018 |
2018-08-04 |
C |
maintained | stable | unclear |
7/9 |
2/9 |
| Q1 2018 |
2018-05-09 |
D |
maintained | unclear | unclear |
7/9 |
6/9 |
| Q4 2017 |
2018-03-15 |
C+ |
none | unclear | unclear |
7/9 |
2/9 |
| Q3 2017 |
2017-11-04 |
D |
maintained | stable | unclear |
6/9 |
5/9 |
| Q1 2017 |
2017-05-10 |
D |
none | unclear | unclear |
7/9 |
3/9 |
| Q4 2016 |
2017-03-13 |
D |
maintained | accelerating | contracting |
7/9 |
3/9 |
| Q3 2016 |
2016-11-10 |
C+ |
maintained | unclear | contracting |
7/9 |
3/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of ADAP's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
D
Q1 2017 earnings call
2017-05-10
18 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← ACXP All “A” companies
ADBE →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.